Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study
Journal of Huntington's Disease · 2026-11 · 15 (4) · 588-598
DOI: 10.1177/18796397261468475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Huntington's Disease, online erschienen am 14.08.2026. Verfasst von Victor Sung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Movement Disorders, University of Alabama at Birmingham, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Tetrabenazine, Huntington Disease, Adrenergic Uptake Inhibitors, Chorea. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Teva Branded Pharmaceutical Products R&D LLC..
Abstract (Originalsprache)
Introduction
Real-world evidence of deutetrabenazine (DTBZ) treatment for Huntington disease (HD)-associated chorea is limited.
Methods
This is a non-interventional, retrospective chart review study from a Huntington's Disease Society of America clinical practice at the University of Alabama at Birmingham (UAB). Patients had a diagnosis of HD-associated chorea, DTBZ initiation (4/2017–12/2021), ≥2 visits at UAB, and ≥3 months of chorea-related care records post DTBZ initiation. The last Unified HD Rating Scale–Total Maximal Chorea (TMC) score within 3 months prior to DTBZ initiation and first after reaching the last stable dose during follow-up were analyzed.
Results
Among 80 eligible patient charts, mean (SD) age was 52.1 (12.6) years and 45 (56.3%) were female. Fifty patients had pre- and post-DTBZ TMC scores and reached a stable dose, including 30 with no prior tetrabenazine (TBZ) or DTBZ exposure, 8 with prior TBZ exposure with a switch to DTBZ after a gap, and 9 with prior TBZ exposure with a switch to DTBZ without a gap. Mean (SD) TMC score decreased (i.e., improved) by 3.7 (4.5), 7.8 (2.8), and 2.1 (4.2), respectively. Overall, 27 (33.8%) patients had ≥1 adverse event recorded between DTBZ initiation and the first visit with a TMC score after reaching their last stable DTBZ dose or DTBZ discontinuation for those without a stable dose.
Discussion
This real-world study describes improvements in TMC scores among patients with HD-associated chorea treated with DTBZ, regardless of prior treatment. The observed safety profile supports the known safety profile of DTBZ in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Division of Movement Disorders, University of Alabama at Birmingham, Birmingham, AL, USA.
- Analysis Group, Inc., Boston, MA, USA.
- Global Medical Affairs, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
- Global Medical Affairs, Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel.
- Innovative Medicines, Global Clinical Development, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
- Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
ORCID-Profile: Victor Sung, Ayelet Yaari, Mark Forrest Gordon
Förderung
- Teva Branded Pharmaceutical Products R&D LLC.
Zitieren
APA
Sung, V., White, A., Romdhani, H., Sethi, S., Goldschmidt, D., Ayyagari, R., Chaijale, N., Yaari, A., Gordon, M. F., Yang, A., & Ribalov, R. (2026). Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study. Journal of Huntington's Disease, 15(4), 588-598. https://doi.org/10.1177/18796397261468475
Vancouver
Sung V, White A, Romdhani H, Sethi S, Goldschmidt D, Ayyagari R, et al. Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study. Journal of Huntington's Disease. 2026;15(4):588-598. doi:10.1177/18796397261468475
BibTeX
@article{Sung2026,
author = {Sung, Victor and White, Ashley and Romdhani, Hela and Sethi, Sakshi and Goldschmidt, Debbie and Ayyagari, Rajeev and Chaijale, Nayla and Yaari, Ayelet and Gordon, Mark Forrest and Yang, Amy and Ribalov, Rinat},
title = {Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study},
journal = {Journal of Huntington's Disease},
year = {2026},
volume = {15},
number = {4},
pages = {588--598},
doi = {10.1177/18796397261468475}
}
EUVIMED